Obesity in adults: assessment, anti-obesity medication and metabolic risk reduction

Clinical scope and immediate priorities

Obesity is a chronic relapsing disease in which excess adiposity contributes to metabolic, cardiovascular, respiratory, reproductive, musculoskeletal and psychological harm. Body mass index is a screening measure, not a complete assessment of disease severity, and treatment should focus on health outcomes rather than weight alone. Endocrine disorders commonly evolve over weeks or months but can decompensate acutely. Management should distinguish biochemical diagnosis from clinical severity, identify medicines or intercurrent illness that alter physiology, and avoid treating a laboratory value without understanding the patient context. Education and self-management are central to long-term outcomes.

Recognition and differential diagnosis

Assess weight trajectory, waist or central adiposity where used locally, sleep apnoea, diabetes, hypertension, fatty liver disease, osteoarthritis, fertility issues and weight-promoting medicines. Ask permission before discussing weight and avoid language that attributes disease to willpower. Rapid unexplained gain may indicate fluid retention or endocrine/medication contributors. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Evaluate blood pressure, glycaemia, lipids, liver risk and relevant symptoms. Endocrine testing should be targeted rather than routine; most obesity is not caused by hypothyroidism or Cushing syndrome. Explore eating patterns, food access, sleep, mental health, mobility, previous treatment and the patient’s priorities. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Offer structured nutrition, physical activity and behavioural support, recognising that sustained weight loss is biologically difficult. GLP-1 receptor agonist and dual incretin therapies have changed pharmacological treatment and can produce substantial weight loss with cardiometabolic benefit in selected patients. Eligibility, titration, adverse effects and continuation criteria vary by jurisdiction. Metabolic/bariatric surgery remains the most effective durable treatment for severe obesity in appropriate candidates. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Severe obesity with major complications, suspected eating disorder, rapid treatment-related weight loss, pregnancy planning or complex diabetes medication needs warrants multidisciplinary input. Monitor gallbladder, gastrointestinal and nutritional issues with pharmacological or surgical treatment as appropriate. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Long-term maintenance support is necessary because weight regain is common after stopping effective therapy. Track blood pressure, glycaemia, sleep, mobility and quality of life alongside weight.

Common pitfalls and safety checks

Do not use BMI as the sole measure of health impact. Avoid routine broad endocrine panels without clinical clues. Stopping effective pharmacotherapy often leads to weight regain and should be discussed before initiation. Weight stigma can reduce engagement and worsen healthcare avoidance. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Implementation should include medicines access, self-monitoring capability, sick-day education and the patient’s ability to recognise deterioration. Nurses, pharmacists, dietitians and primary-care clinicians often carry much of the longitudinal management, so targets and escalation thresholds should be communicated clearly. Laboratory monitoring should have an owner and an interval linked to the treatment decision. When recommendations differ among national diabetes or endocrine organisations, adapt the operational target to comorbidity, pregnancy, frailty and local medicine availability rather than pursuing a number in isolation.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.